you, of quarter receiving the Thank for the Corcept. of as to and an repeat XXXX Korlym number each of the year dedication number medication. skill is Thanks prescribers first-time of the and patients increased our was excellent Charlie. commercial team,
growth XX% Our million to revenue and expect grew continue. we to $XXX.X
$XXX between As Charlie we million revenue of guidance $XXX and mentioned, million our and we At $XXX in had million. year-end, reaffirmed investments. XXXX have cash
cortisol pursue optimal modulators. to us development allows selective position our proprietary financial the of strong Our
in Cushing's and of Success are programs syndrome, any weight medication to benefit represent produce Corcept's These advancing. NASH many programs could gain antipsychotic-induced Our patients. tumors, of in them future. solid a great
this our of actively We our As are relacorilant, call trial most Phase patients III treat syndrome. to in of patients you planned with GRACE. study enrolling know, to Korlym we successor Cushing's
and fourth are placebo to compared is degree to Expected patients receiving GRACE received second submit for Cushing's States, to rest has patients double-blind, GRACE's to are relapse exhibit parts. treat weeks. glucose XXX Korlym half in or continue the receiving Israel. label quarter randomized hypertension -- syndrome of withdrawal relacorilant an receiving a XX patients. which now of XX rate are Europe relacorilant Those at In opened those patients this who in the the enrollment initial in X for placebo. improvements during XXXX. plan randomized in sites its relacorilant has phase, open We the United with and NDA phase, relacorilant, prespecified placebo-controlled primary The in endpoints switched and metabolism trial to phase.
we will be syndrome open GRADIENT named this a syndrome double-blind, Later been a is plan adrenal not this have we which of to second trial Cushing's relacorilant GRADIENT. etiology quarter, have Phase to an rigorously caused of adenoma. III whose placebo-controlled trial, Cushing's Patients with studied. by patients treat
months, with Many will their in relacorilant they in at indolent investigators a participate sites primary more XXX States glucose being usually and or endpoints also course Patients health enrollment and in will Europe. United for the hypertension. outcomes poor. have Although of either of X patients GRADIENT. of metabolism has for a placebo receive GRADIENT planned disease, the improvement the are GRACE
actively trial enrolling demonstrate and trials syndrome business. to GRACE begin, contribution briefly purpose like I'd to about to to With patients on our is the of to Cushing's the make these development expect the the relacorilant. The we comment of safety long-term of GRADIENT GRACE efficacy definitively and
what Phase we Its comparable points were data similar study. in very to Korlym's pivotal been efficacy have observed results II at Relacorilant's encouraging. time
tab at presenting data available poster of is Association Congress Events at the of the Past II Annual website. Our Endocrinologists relacorilant's American Clinical Phase Investors our
confirm to important relacorilant's promising GRACE's safety profile. of Another is objectives
is label Korlym patients, for major side the medication short, includes require by As that is binds to Korlym's the which effective box abortifacient. required ingredient, controlled. that to of the is which pregnancy. termination most abortion the an mifepristone, potently as receptor, many its Korlym effects the Korlym's active and causes FDA a distribution why use tightly be PR for warning same it for it pills, limit makes its black as progesterone serious warning,
Cushing's women can a men causes low with In Approximately condition known Korlym addition bleeding as Korlym's and in of also Korlym are of patients different affinity approximately in who PR and Hypokalemia dangerously patients, adverse become many X/X women discontinuation. to it and mechanism, of affects terminating These age. potassium women. take endometrial hospitalization pregnancy, By their thickening syndrome causes the hypokalemia. result XX% in effects equally. a to vaginal regardless
PR. discontinuation, off-target patients PR thickening than experienced Korlym, It bleeding. It of not not the is XX% cause endometrial of these It in affinity, and leading adverse not Korlym effects. and does close and the does not effects but arising appear does cause of such causes abortion not More the requires monitoring. hypokalemia. cause other continued is is manageable, pivotal trial potassium. also to low Unlike does Korlym's the bind pill relacorilant one relacorilant as Hypokalemia vaginal from to
most Korlym's demonstrated characteristic major will cortisol relacorilant off-target an safety GRACE, and efficacy that by confirmed does are not development in the cause effective constitute II relacorilant has advance, Phase significant its If a through medical effects. modulator
Cushing's hyperplasia. by Cushing's etiology might hypercortisolism. syndrome. be modulation and as Korlym, a investment will study serious, expectation syndrome patients a has of GRADIENT GRACE with better indication approval same relacorilant's studied the Although same of a our is of as NDA, rather with part syndrome, for our development GRADIENT lead rigorously candidate, narrow GRADIENT patients a GRACE, caused and of treatment is what securing or Where a different Cushing's the purpose. cortisol serves adenomas but test drug purpose, to care to for yet is is not patients a part long-term adrenal with adrenal will not for findings relacorilant, GRADIENT's that GRADIENT successor required characterized
Preclinical and by that and to antipsychotic disorders. I'll our metabolic and disorders medications options. show modulation NASH. potential a nonalcoholic Serious data that weight such treatment antipsychotic the in good bipolar clinical of gain few people or both millions update olanzapine now steatohepatitis provide disorder there risperidone which medications caused other and for Millions brief cortisol treat affect serious of has people to program conditions. of schizophrenia, treat depend as on are and
serious drugs metabolic leading and effects, sustained and rapid cause patients Unfortunately, schizophrenia. these gain, side not is weight hyperlipidemia. suicide, cause of hyperglycemia Cardiovascular disease, in the with including life-saving death
Journals taking their significantly the morbidities them. the The We mifepristone and olanzapine weight caused felt reduced medications, double-blind, seen demonstrated that a mifepristone other risperidone needed and for because mifepristone the to be not in these ill in we pill, in disorder often are XXXX. December common XXXX trials as of subjects. in cannot and a in that in Obesity who and stop patients active ingredient October widely placebo-controlled then the the published could gain medical were Unfortunately, for adverse results Therapy abortion addition effects and treatment by is advance in Advances such effects distributed. by In healthy in reason
development. for preventing can risperidone-induced be receptor proprietary weight and therefore, more it What's is on is Our in a and milligram gain. more modulator, to widely per mifepristone miricorilant, and reversing cortisol distributed basis even in selective suitable olanzapine models, animal potent
Our highly XX gain either XX those healthy clear placebo. of produced first or clinical receive miricorilant less XX of statistical XX days. and of weight received Day milligrams subjects for both Each olanzapine and daily at study subjects encouraging measured significance, who of miricorilant results. placebo Day milligrams who X received than miricorilant With XXX
ALT of and short damage that protective liver. demonstrating miricorilant's increased duration especially of temporarily may enzymes are of increase suggests results the the which and miricorilant, activity at therapy, addition, given In miricorilant liver These subjects [indiscernible]. AST, olanzapine less markers the have markedly receiving that effects in treatment onset encouraging,
a Philadelphia. Association will II study with schizophrenia, This weight began study last be this starting called medication. GRATITUDE. is Full Annual April of who antipsychotic patients we trial presented have rapidly after in miricorilant in from Psychiatric of results at Phase year, the Meeting American the Late gained this
Study in is patient's existing psychiatric medication. XXX or to Planned loss, participants condition. improving while primary antipsychotic or weight milligrams study's receive of maintaining patients. addition miricorilant either endpoint The is placebo this XXX their enrollment
increases mentioned have for use we've greatly been suitable formulation developing on the a I in commercially and Phase As miricorilant of III drug's calls, bioavailability. prior that
dose We a to double-blind, we which plan at with to we expect of in miricorilant cohort weight higher the available fourth will significantly antipsychotic-induced gain. year, a quarter be a long-standing receiving patients Thus, GRATITUDE. of of that open point placebo-controlled to add trial by II also Phase patients this formulation
treat animal fibrosis. benefit Finally, we patients liver to In to placebo-controlled open disorder with of a study. a by and Phase with year-end. plan Miricorilant's prevents II miricorilant to patients both reverses miricorilant merits double-blind, clinical NASH potential serious liver trial models, and widespread fatty
turn by receptor which of tumors now apoptosis, program. activation chemotherapy to GR. the Unfortunately, achieves cell GR intended its mechanism is glucocorticoid or will solid inhibits death, which Many programmed oncology I our effect. cortisol express the
the the with We A disease last conference Celgene's tumors. allow ASCO their taxane-based shrank or with X control. with longer may Abraxane, patients a growing tumors ovarian particular in XX relacorilant cancer cancer was benefit. for shrinkage results a and hypothesis the year, presented in drug, with of patients modulator with weeks. ceased coadministering cancer Of duration X cancer we our in ovarian are metastatic Tumor patients I/II of that solid for achieve achieved XX variety of pancreatic maximum XX to weeks with durable longer. exhibited The its cortisol of either patients tumor Meaning combination were from weeks. Phase or lasted X patient testing benefit. striking, chemotherapy XX note data XX metastatic study nab-paclitaxel, pancreatic At of than metastatic shrinkage
progressed added taxanes, during All and prior tumors was had of treatments these multiple with relacorilant patients' including heartening. treatment when of surprising was some to lines therapy, responded their that
Past website. tab Investors available the presenting at of Events poster is data ASCO Our these our
in at Europe. a with unresectable Phase is endpoint secondary survival of United ovarian II the sites including and The or conducting benefit. endpoints controlled duration nab-paclitaxel metastatic are relacorilant plus of States trial cancer primary patients overall with and XXX-patient in We survival progression-free
to expect first study next report results We in this of year. half the of
poor very We cancer, patients relacorilant preparing a in pancreatic Phase disease good treatment a III with metastatic no plus prognosis to nab-paclitaxel start with a options. are of trial also and
we have a identified accelerated could Following approval. discussions with FDA, the that design trial support
provided serious prior of FDA you fill being confirmatory an of that accelerated unmet are that is faster to granted. conditions medical program trials and familiar approval drugs initiated or those more it, not For approval need X permits with approval treat an
this enrolling trial in patients begin We quarter. next expect to
Cortisol immunosuppressant. body's the natural is
can or severity patients frequently also the know of unresectable we relacorilant the to in this the by patients checkpoint with In be syndrome Phase beneficial with PD-X treats XX symptoms experience. We effect survive these that Although inhibitor metastatic Korlym cortisol Cushing's a cells of trial prevalence plus pembrolizumab, of tumor it KEYTRUDA, Merck's drug modulation autoimmune and disorders, it adrenal cancer. for reducing the second makes to launch plan easier proliferate. Ib quarter, and
Our syndrome symptoms trial its the of can, suppression cortisol, by both maximum examine will patients caused Cushing's effect. and the help these relacorilant by the reducing achieved immunotherapy immune excess whether treat
to Unfortunately, of route. prostate prostate are androgen cells in a year, Stimulation may Finally, combined proliferate, to help the patients their to this causes to cortisol. stimulated University with deprivation exicorilant, medications are cancer. expect enzalutamide, cells with by such is conclude cortisol cortisol receptor with trial Adding standard antagonist with cancer The modulation to cortisol androgen This exposed XTANDI, when may leading tumor at prostate being trial modulator, treat selective why therapy in of cancer. plus Pfizer's a also of castration-resistant a androgen escape this relacorilant growth enzalutamide, as block Investigators which often we shifts tumor enzalutamide of Chicago dose-finding therapy. enzalutamide receptor our is drug a prostate castration-resistant patients disease. antagonism
excellent Corcept had an XXXX.
and Our Cushing's added syndrome patients. business physicians
growth more to will this that revenue our $XXX expect with million $XXX have year-end, and and We million, million guidance year. reaffirmed in balance of investments grow of at $XXX a cash XXXX
of to our disorders. able a the are treatments serious as variety We proprietary of potential for compounds fund fully development
is GRACE patients. trial actively Our enrolling
in stated, we to NDA As an plan quarter syndrome year. previously the for of next submit in relacorilant fourth Cushing's
placebo-controlled III or syndrome we syndrome, adenomas Phase quarter, trial, by in study, a relacorilant's This examining adrenal Cushing's understudied of our an Cushing's double-blind hyperplasia. activity adrenal GRADIENT will open etiology caused
Phase ovarian accruing II in is plus controlled Our patients. cancer actively nab-paclitaxel trial of advanced relacorilant
to half results of the first expect We XXXX. in report
provide with the patients second metastatic plan approval. Phase plus we with in or quarter, basis study adrenal pancreatic a of relacorilant we start cancer Phase in combination a checkpoint cancer. to open quarter, of with patients Ib plan Next in a accelerated to inhibitor in may that for unresectable metastatic trial the III relacorilant Also nab-paclitaxel
patients combination castration-resistant Finally, our prostate recent dose-finding Miricorilant's enrolling cancer II to is exicorilant weight actively gain conclude for the trial year-end. with in in Phase metastatic of patients. we expect treatment antipsychotic-induced enzalutamide with trial of by
other plan questions. an and by improved with two miricorilant weight with II year-end, NASH. to here use we X long-standing And stop patients patients trials, formulation for of the Phase antipsychotic-induced gain in in placebo-controlled I'll double-blind, in
